1	Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection
2	of SARS-CoV-2 in Clinical Laboratories
3	
4	Joshua A. Lieberman ¹ , Gregory Pepper ¹ , Samia N. Naccache ² , Meei-Li Huang ^{1,3} , Keith R.
5	Jerome ^{1,3} , Alexander L. Greninger ^{1,3}
6	
7	¹ Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA
8	² LabCorp Seattle, Department of Microbiology, Seattle, WA
9	³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
10	
11	
12	Running Title: Commercial SARS-CoV-2 Assay Comparison
13	

14 Abstract

15 Multiple laboratory developed tests and commercially available assays have emerged to meet 16 diagnostic needs related to the SARS-CoV-2 pandemic. To date, there is limited comparison 17 data for these different testing platforms. We compared the analytical performance of a 18 laboratory developed test (LDT) developed in our clinical laboratory based on CDC primer sets 19 and four commercially available, FDA emergency use authorized assays for SARS-CoV-2 20 (Cepheid, DiaSorin, Hologic Panther, and Roche Cobas) on a total of 169 nasopharyngeal swabs. 21 The LDT and Cepheid Xpert Xpress SARS-CoV-2 assays were the most sensitive assays for SARS-22 CoV-2 with 100% agreement across specimens. The Hologic Panther Fusion, DiaSorin Simplexa, 23 and Roche Cobas 6800 only failed to detect positive specimens near the limit of detection of our CDC-based LDT assay. All assays were 100% specific, using our CDC-based LDT as the gold 24 25 standard. Our results provide initial test performance characteristics for SARS-CoV-2 RT-PCR 26 and highlight the importance of having multiple viral detection testing platforms available in a 27 public health emergency.

28 Introduction

Since the first infection with SARS-CoV-2 was detected in the United States in January 2020 (1), there has been an exponential growth in cases and deaths (2). At the time of this writing, the US case count exceeds 600,000 with more than 30,000 deaths and considerable geographic heterogeneity (2, 3). Despite social distancing policies, the outbreak of Covid-19, the disease caused by SARS-CoV-2, continues to grow and threatens to overwhelm hospital systems in multiple states (2).

35 The explosion of Covid-19 cases in the United States has highlighted the critical role 36 diagnostic testing plays in medical and public health decision making in containing and mitigating the SARS-CoV-2 pandemic. Reliable test results enable appropriate utilization of 37 38 scarce hospital resources, including personal protective equipment (PPE) and negative pressure 39 isolation rooms, as well as public health resources for contact tracing or isolation decision-40 making (4). In rapid succession in March 2020, multiple assays have become available including both FDA-EUA test platforms and laboratory developed tests (LDTs) for use in high-complexity 41 42 clinical laboratories. To solve supply chain difficulties, clinical laboratories have had to 43 implement multiple assays using scarce reagent resources, rendering thorough comparisons 44 challenging. A clear understanding of the analytical parameters of these options is important to 45 help guide assay selection by clinical laboratories when supply chain considerations subside (4). 46 Reverse transcription polymerase chain reaction (RT-PCR) is the mainstay of SARS-CoV-2

detection *in vitro* (5). FDA EUA authorized assays for SARS-CoV-2 have mostly targeted two loci of the positive sense, single-stranded RNA virus by real time RT-PCR and are reported qualitatively. Our laboratory has recently reported that the CDC N2 and WHO E-gene

primer/probe sets are among the most sensitive and have detected no false positives in our LDTs (6). FDA EUA authorized platforms use a variety of different primer/probe sets, resulting in the potential for differing analytical sensitivities. In addition to differing analytical sensitivities, commercially available platforms have important operational differences including integrated sample extraction, run time, random access, and acceptable sample types.

Here, the performances of one LDT-EUA assay developed in our clinical laboratory and four FDA-EUA cleared assays were evaluated for detection of SARS-CoV-2. The FDA-EUA cleared assays included were: Hologic Panther Fusion (both RUO and EUA versions, EUA version performed at two study sites), DiaSorin Simplexa COVID-19 Direct (EUA), Cepheid Xpert Xpress SARS-CoV-2 (EUA), and Roche Cobas 6800 (EUA). Test performance characteristics of each RT-PCR were determined compared to our reference LDT assay.

61

62 Materials & Methods

Specimen collection and consensus panel selection. Nasopharyngeal (NP) swabs (N =63 64 169) were collected from patient specimens submitted to the University of Washington Medical Center laboratories for clinical diagnostic testing. LDT performance was validated based on 65 detection of 20 of 20 positives sent by the Washington State Public Health Laboratory in early 66 67 March. Residual clinical samples were used for validation/verification of each subsequent 68 instrument, including a common panel of 26 specimens (12 positive, 1 inconclusive, and 13 negative) tested at UW by the UW CDC EUA-based LDT (CDC LDT), DiaSorin Simplexa (positives 69 70 only), Roche Cobas 6800, and tested at LabCorp Seattle on the Cepheid Xpert Xpress, and 71 Panther Fusion (12 positives only). Additional residual (N = 115) specimens were tested at UW

72 on individual assays and compared to the reference method (LDT): Panther Fusion (RUO), N =73 36; Panther Fusion (EUA)-UW, N = 20; DiaSorin Simplexa (EUA), N = 19; Cobas 6800, N = 40. 74 Finally, 28 specimens were used to compare the SARS-CoV-2 assay on the UW Panther Fusion with the DiaSorin Simplexa assay. All same-sample comparisons were performed on specimens 75 76 stored at 4°C for less than 72 hours with no freeze-thaws. Inconclusive results (one of two 77 targets detected) were considered positive due to the high specificity of all assays and limited 78 cross-reactivity seen for SARS-CoV-2 primer sets. This work was approved under a consent 79 waiver from the University of Washington Institutional Review Board.

80

Sample processing. For the UW CDC LDT, total nucleic acid (NA) was extracted from 81 82 200µL of VTM on the Roche MP96 and eluted in 50µL of elution buffer. Real-time RT-PCR was 83 set up on 5µL of eluate using the CDC N1, N2, and RP (or Exo internal control) primers and run 84 on ABI 7500 real-time PCR instruments as reported previously (6). For the Hologic Panther Fusion, 500µL of VTM was transferred to lysis buffer in manufacturer-provided tubes and 85 86 loaded directly on the instrument. For the DiaSorin Simplexa and Cepheid Xpert Xpress, 50µL or 87 300µL of VTM sample respectively was loaded directly into the reaction cartridge with 88 integrated sample process. For the Roche Cobas 6800, 600µL of specimen VTM was added to a 89 barcoded 12x75mm secondary tube and loaded directly on the instrument.

90

91 Results

92 **Panther Fusion SARS-CoV-2**. The Panther Fusion SARS-CoV-2 assay was tested first as research 93 use only (RUO) reagents (N = 36), and then again following FDA authorization (N = 20). Both

Panther Fusion RUO and EUA assays were slightly less sensitive than the CDC-based LDT, missing one positive/inconclusive in each sample set (Table 1a/b). One additional specimen was initially negative with the RUO reagents but was detected upon repeat with the Panther Fusion EUA assay. Discordant specimens were either inconclusive (one target of two detected) or had high average CTs (>37) by the CDC LDT test. All 29 negative specimens generated "Not detected" results by the Hologic Panther Fusion SARS-CoV-2 assay.

100

101 **DiaSorin Simplexa SARS-CoV-2.** We next compared the DiaSorin Simplexa SARS-CoV-2 assay to 102 our CDC-based LDT. All 19 specimens (11 positives and 8 negatives) demonstrated complete 103 concordance between the two platforms (Table 2a) with lower CTs recovered by the DiaSorin 104 compared to the LDT on all specimens (average CT difference -2.1 [IQR -2.3 - -1.7]). When we 105 compared SARS-CoV-2 detection on the DiaSorin Simplexa to the Hologic Panther Fusion, all 16 106 Hologic Panther Fusion positives were detected by the DiaSorin Simplexa, while the DiaSorin 107 Simplexa generated one additional positive in the 12 specimens that were negative by the 108 Hologic Panther Fusion (Table 2b). This discordant specimen was detected by the CDC-based 109 LDT with CTs of 36.8 (N1) and 35.8 (N2), confirming the DiaSorin Simplexa result.

110

Roche Cobas SARS-CoV-2. We next compared the Roche Cobas SARS-CoV-2 assay to our CDC
LDT. All 20 negatives demonstrated complete concordance between the two platforms (Table
3). One of the 20 positives was not detected by the Roche assay. This specimen had CTs of 38.0
(N1) and 37.4 (N2) in the LDT. Across the 20 positive specimens, CTs were only slightly higher

on the Roche Cobas assay compared to the CDC-based LDT, with an average CT difference of
0.6 [IQR -0.1 - 1.5].

117

118 Five-way same-sample comparison including Cepheid Xpert Xpress SARS-CoV-2 assay

119 After performing the above pairwise comparisons, we next compared twenty-six specimens (13 120 positive, 13 negative) from another high-complexity hospital laboratory (LabCorp Seattle). All 121 26 were also tested on the Cepheid Xpert Xpress SARS-CoV-2 assay (Table 4). All specimens 122 with CT < 35 on the CDC-based LDT were detected by all platforms, and all specimens not 123 detected by the Cepheid Xpert were not detected by two other platforms examined (CDC LDT, 124 Roche Cobas). One of 13 positive specimens was a presumptive positive on the Cepheid assay 125 (E-gene CT 42.6, N2-gene negative); upon repeat per package insert, the N2-gene was detected 126 at CT 42.7 but the E-gene was not detected, yielding a positive result. The CDC LDT 127 demonstrated 100% concordance with the Cepheid Xpert Xpress, also detecting the extremely 128 low viral load specimen above as an inconclusive (N1 37.4, N2 not detected). No other assay 129 detected SARS-CoV-2 RNA in this specimen. In addition, the DiaSorin Simplexa failed to detect a 130 positive specimen that on repeat was detected only by the ORF1ab primer set.

131

132 Discussion

This analysis compared the performance characteristics of several *in vitro* diagnostic real time RT-PCR assays to detect SARS-CoV-2 in high-complexity clinical laboratories in one of the early US epicenters of the COVID-19 pandemic. The results demonstrated excellent performance of a CDC-based LDT and the Cepheid Xpert Xpress, concurring with a previous

evaluation that demonstrated high sensitivity of the E-gene and N2 primer sets used by the 137 138 Cepheid assay (6). The Panther Fusion was somewhat less sensitive than either the LDT or the 139 DiaSorin; however, the Panther Fusion detected SARS-CoV-2 RNA in one specimen that was 140 inconclusive (1 of 2 targets detected, thus presumed positive) by the UW CDC LDT. The Roche 141 assay performed on the Cobas 6800 platform detected 28/30 positive samples; both of these 142 discordant specimens had low viral titers (UW CDC LDT C_T >37) and one was the inconclusive 143 specimen. Therefore, we conclude that all the tested assays show good sensitivity for the 144 detection of SARS-CoV-2, with the UW CDC LDT and Cepheid Xpert Xpress SARS-CoV-2 assays 145 having the best and similar sensitivity, followed by the Roche Cobas 6800, DiaSorin Simplexa, 146 and Panther Fusion SARS-CoV-2 assays.

Our results are chiefly limited by the small sample sets used to compare these different 147 148 assays as well as asynchronous comparisons that only allowed for pairwise comparisons early in 149 the pandemic. For instance, these asynchronous panels most greatly affected our CDC LDT versus Hologic Panther Fusion comparison, which had a greater proportion of high CT positive 150 151 specimens that resulted in a lower measured sensitivity for the Panther Fusion. . In clinical 152 practice, the minor differences in sensitivity are likely to have little effect on Hologic Panther 153 Fusion SARS-CoV-2 assay performance on VTM specimens, given the CT ranges we have 154 observed in our clinical populations.

Despite their limitations, these data provide a basis for differences in analytical sensitivity at different CTs that may be seen between platforms. For instance, recent reports have demonstrated a slightly higher analytical sensitivity of the Cepheid Xpert Xpress SARS-CoV-2 assay compared to the Roche Cobas SARS-CoV-2 test, and a slightly lower sensitivity of

159 the DiaSorin Simplexa SARS-CoV-2 assay compared to a modified CDC assay, both of which are 160 concordant with our data (7, 8). We also note that, while analytical sensitivity is of critical 161 importance, many other considerations factor into assay platform selection including assay 162 availability, cost, turnaround time, and throughput. 163 Our results provide an early assessment of performance characteristics of five separate 164 assays for the detection of SARS-CoV-2. During March 2020, reagent availability for SARS-COV-2 165 RT-PCR assays was heavily constrained, necessitating more limited assay comparisons. All 166 platforms examined here had acceptable performance criteria for testing during the early part 167 of this pandemic. As the supply chain for SARS-CoV-2 RT-PCR attempts to catch up with testing 168 demand, we look forward to additional assay comparison data.

169

170 References

- 171 1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K,
- 172 Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X,
- 173 Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK. 2020. First Case of
- 174 2019 Novel Coronavirus in the United States. N Engl J Med 382:929–936.
- 175 2. IHME COVID-19 health service utilization forecasting team, Murray CJ. 2020. Forecasting
- 176 COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in
- the next 4 months. preprint, Infectious Diseases (except HIV/AIDS).
- 178 3. Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in
- real time. The Lancet Infectious Diseases \$1473309920301201.
- 180 4. Babiker A, Myers CW, Hill CE, Guarner J. 2020. SARS-CoV-2 Testing. Am J Clin Pathol.
- 181 5. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S,
- 182 Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, van der Veer B, van den Brink S,
- 183 Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
- 184 Koopmans MPG, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by
- 185 real-time RT-PCR. Euro Surveill 25.
- 186 6. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H,
- 187 Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection
- 188 Assays using Seven Different Primer/Probe Sets and One Assay Kit. Journal of Clinical
- 189 Microbiology.

190	7.	Moran A, Beavis KG, Matushek SM, Ciaglia C, Francois N, Tesic V, Love N. 2020. Th

- 191 Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche Cobas
- 192 SARS-CoV-2 Assays. Journal of Clinical Microbiology.
- 193 8. Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. 2020. Comparison
- 194 of Abbott ID Now, DiaSorin Simplexa, and CDC FDA EUA methods for the detection of
- 195 SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-
- 196 19. Journal of Clinical Microbiology.
- 197
- 198
- 199

Tables

			Panther Fusion SARS-
	UW	LDT	CoV-2 (RUO)
Sample ID	N1 Ct	N2 Ct	Orf1ab/2ab
56	27.2	27.8	23.2
07	26.2	25.5	22.8
46	23.9	25.8	21.4
81	23.8	24	25.5
40	23.8	23.9	23.7
66	17.7	17.1	19.7
26	24.9	24.6	27
85	35.98	35.8	33.5
82	29.1	29.7	29.6
37	23.1	22.3	22
70	29.7	28.9	30.5
29	29.4	28.2	26.3
68	29.4	28	28.3
04	25.9	25.4	24.9
95	35	37	35.3
55	39.2	39	NDET
14	36.3	NDET	35.5

Table 1a. CDC-based LDT versus Hologic Panther Fusion RUO

19/19 CDC LDT negatives were negative by Hologic Panther Fusion EUA

Table 1b. CDC-based LDT versus Hologic Panther Fusion EUA

	UW	LDT	Panther Fusion SARS- CoV-2 (EUA)
Sample ID	N1 Ct	N2 Ct	Orf1ab/2ab
100	30	30.4	29
67	20.3	20.8	19.3
76	27.1	27.6	31.1
17	23.4	23.6	20.5
02	18.1	17.2	19.3
59	29.4	29.8	31.7
97	18.4	17	18.9
52	16.8	15.9	16.9
90	36.1	38.4	NDET/38.1
79	38.4	NDET	NDET/NDET
10/10 00 0100			

10/10 CDC LDT negatives were negative by Hologic Panther Fusion EUA

NDET, Not Detected

Table 2a. CDC-based LDT versus DiaSorin Simplexa EUA

	UW LD	т	UW DiaSorin		
Sample ID	N1 Ct	N2 Ct	S-gene	ORF1ab	
1A Pos	27.9	27.6	25.2	25.6	
2A Pos	18.6	19.1	18.0	18.1	
3A Pos	27.8	27.5	25.2	26.0	
4A Pos	28.2	27.6	25.8	26.5	
5A Pos	31.6	31.3	28.5	29.0	
6A Pos	33.9	34.6	31.0	31.6	
7A Pos	31.1	31.5	28.8	29.2	
1C Pos	34.1	33.9	31.5	32.1	
2C Pos	33.7	34.6	32.7	32.4	
3C Pos	32.4	32.3	29.8	30.4	
4C Pos	34.9	34.8	32.7	33.6	

8/8 negatives by UW LDT were negative by DiaSorin

Table 2b. Hologic Panther Fusion EUA versus DiaSorin Simplex EUA

	Panther Fusion			
	SARS-CoV-2 (EUA)	DiaSorin		
Sample ID	Orf1ab/2ab	S-gene	ORF1ab	
65	35.2	37.2	32.9	
38	33.6	33.7	34	
83	31.5	28.5	27.7	
13	30.7	27.2	27	
39	30.1	30.7	29.2	
10	29.6	29.1	28.1	
56	28.7	27	26.4	
31	26.5	24.4	22.8	
33	25.4	24.8	24.4	
60	23.3	21.1	20.5	
92	22.5	23	23.4	
98	21	18.1	17.3	
40	18.2	15	14	
25	17.9	16.1	15.6	
13	16.7	15.1	14.3	
52	15.6	13.2	12.3	
42*	NDET	31.8	32.7	
44/42 11		- ·	•	

11/12 negatives by Hologic Panther Fusion EUA were negative by DiaSorin

Table 3. CDC-based LDT versus Cobas 6800 SARS-CoV-2

	UW LDT		UW Cobas 6800			
mple ID	N1 Ct	N2 Ct (ORF1ab	E-gene		
136	26.7	27.6	26.9	27.2		
560	16.4	16.3	19.0	19.6		
578	23.8	24.9	25.4	26.3		
757	23.4	24.2	24.7	25.0		
982	20.3	20.9	21.9	22.2		
853	20.4	21.5	21.6	21.5		
998	14.6	15.6	15.9	16.3		
334	20.2	21.4	21.5	21.9		
571	18.0	18.9	17.9	18.2		
108	35.5	35.0	31.8	34.7		
188	36.4	35.7	35.4	37.2		
599	24.7	25.6	26.7	27.1		
995	25.2	26.4	26.4	26.8		
336	29.1	29.5	31.1	31.6		
866	31.3	31.4	31.1	32.0		
232	36.3	36.4	32.3	35.2		
323	28.6	28.7	29.5	30.7		
309	14.3	15.4	14.5	14.8		
277	19.7	21.4	20.4	20.5		
018	38.0	37.4	NDET	NDET		
20/20 negatives by UW LDT were negative by Cobas 6800						
negatives by UV	W LDT were	e negative by	Cobas			

LabCorp

Table 4. Same-sample comparison of five testing platforms for SARS-CoV-2

							LabCorp Seattle		Seattle
									Panther
									Fusion
Devel	UW	LDT	UW Dia	aSorin	UW Coba	as 6800	Xpert Xpres	s Sars-CoV2	SARS-CoV-2
Panei D	N1 Ct	NZ Ct	S-gene	ORF1ah	ORF1ab	E- gene	F-gene	N2 Ct	Orf1ab/2ab
Neg 01		NDFT	N.D.	N.D.		NDFT	NDFT	NDFT	N.D.
Neg 02	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 03	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 04	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 05	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 06	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 07	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 08	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 09	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 10	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 11	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 12	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Neg 13	NDET	NDET	N.D.	N.D.	NDET	NDET	NDET	NDET	N.D.
Pos 01	30.7	30.2	29.2	30	30.5	31.1	31.7	33.8	31
Pos 02	28.5	28.7	27.2	28	29.6	30.5	29.2	31.6	29.7
Pos 03	28.6	28.8	27.3	28.4	30.4	32.2	28.7	31.4	31.2
Pos 04	25.2	24.4	22.4	23.8	26.1	26.2	25.4	25.9	25.2
Pos 05*	35.4	35.6	NDET/NDET	NDET/34.5	33.6	36.2	37.6	37.5	35
Pos 06	27.2	26.7	25	26.9	26.4	27.3	26.8	29.5	26.3
Pos 07	26.3	25.5	22.2	23.3	25.9	26.1	26	28.1	24.7
Pos 08	35.8	34.4	33.6	33	31.7	34.1	35.9	38.5	36.3
Pos 09	18	17.6	15.3	16.4	19.4	19.5	18	19.3	18.6
Pos 10	31.9	32.1	31.1	31.1	31.9	33.6	31.7	34.2	32.2
Pos 11	31.3	31.3	28.1	29.2	30.5	32	31.2	34.6	N.D.
Pos 12*	37.4	NDET	NDET	NDET	NDET	NDET	NDET/42.6	42.7/NDET	NDET
Pos 13	32.6	33.9	32.5	32.5	NDET	35.7	38.1	40	37.1

*Known positive patients in process of clearing virus

NDET, Not Detected

N.D., Not Done

209

210

211